A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models

Authors

  • Vijaykumar M. Baragi,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Search for more papers by this author
  • Gabriel Becher,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Alison M. Bendele,

    1. Boulder Biopath, Boulder, Colorado
    Search for more papers by this author
  • Ralf Biesinger,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Harald Bluhm,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Jürgen Boer,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Hongbo Deng,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Rory Dodd,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Current affiliation:
    1. Ariad Pharmaceuticals, Cambridge, Massachusetts
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Michael Essers,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Tim Feuerstein,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Brian M. Gallagher Jr.,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Christian Gege,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Matthias Hochgürtel,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Michael Hofmann,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Andreas Jaworski,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Lixia Jin,

    1. Amgen Inc., South San Francisco, California
    Search for more papers by this author
  • Andrew Kiely,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Current affiliation:
    1. Aldrich, St. Louis, Missouri
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Brian Korniski,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Current affiliation:
    1. Pfizer, New York, New York
    Search for more papers by this author
  • Heiko Kroth,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Darrell Nix,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Current affiliation:
    1. Gloucester Pharmaceuticals, Inc., Cambridge, Massachusetts
    Search for more papers by this author
  • Bert Nolte,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Dorothea Piecha,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Timothy S. Powers,

    Corresponding author
    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Current affiliation:
    1. Amgen Inc., Thousand Oaks, California
    • Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

    • Drs. Powers and Sucholeiki own stock in Amgen.

  • Frank Richter,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Matthias Schneider,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Current affiliation:
    1. X2 Pharma, Heidelberg, Germany
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Christoph Steeneck,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Irving Sucholeiki,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

    • Drs. Powers and Sucholeiki own stock in Amgen.

  • Arthur Taveras,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Current affiliation:
    1. Biogen Idec, Cambridge, Massachusetts
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Andreas Timmermann,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Joshua Van Veldhuizen,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Juergen Weik,

    1. Alantos Pharmaceuticals, Heidelberg, Germany
    Search for more papers by this author
  • Xinyuan Wu,

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Current affiliation:
    1. Hydra Biosciences, Cambridge, Massachusetts
    Search for more papers by this author
    • Drs. Bluhm, Deng, Gallagher, Gege, Hochgurtel, Kiely, Powers, Richter, Schneider, Steeneck, Sucholeiki, Taveras, Van Veldhuizen, Wu, Ms Dodd, and Mr. Biesinger are authors of a pending application for a patent on the MMP inhibitors investigated in this study.

  • Bing Xia

    1. Alantos Pharmaceuticals, Cambridge, Massachusetts
    Search for more papers by this author

Abstract

Objective

Matrix metalloproteinases (MMPs) have long been considered excellent targets for osteoarthritis (OA) treatment. However, clinical utility of broad-spectrum MMP inhibitors developed for this purpose has been restricted by dose-limiting musculoskeletal side effects observed in humans. This study was undertaken to identify a new class of potent and selective MMP-13 inhibitors that would provide histologic and clinical efficacy without musculoskeletal toxicity.

Methods

Selectivity assays were developed using catalytic domains of human MMPs. Freshly isolated bovine articular cartilage or human OA cartilage was used in in vitro cartilage degradation assays. The rat model of monoiodoacetate (MIA)–induced OA was implemented for assessing the effects of MMP-13 inhibitors on cartilage degradation and joint pain. The surgical medial meniscus tear model in rats was used to evaluate the chondroprotective ability of MMP-13 inhibitors in a chronic disease model of OA. The rat model of musculoskeletal side effects (MSS) was used to assess whether selective MMP-13 inhibitors have the joint toxicity associated with broad-spectrum MMP inhibitors.

Results

A number of non–hydroxamic acid–containing compounds that showed a high degree of potency for MMP-13 and selectivity against other MMPs were designed and synthesized. Steady-state kinetics experiments and Lineweaver-Burk plot analysis of rate versus substrate concentration with one such compound, ALS 1-0635, indicated linear, noncompetitive inhibition, and Dixon plot analysis from competition studies with a zinc chelator (acetoxyhydroxamic acid) and ALS 1-0635 demonstrated nonexclusive binding. ALS 1-0635 inhibited bovine articular cartilage degradation in a dose-dependent manner (48.7% and 87.1% at 500 nM and 5,000 nM, respectively) and was effective in inhibiting interleukin-1α– and oncostatin M–induced C1,C2 release in human OA cartilage cultures. ALS 1-0635 modulated cartilage damage in the rat MIA model (mean ± SEM damage score 1.3 ± 0.3, versus 2.2 ± 0.4 in vehicle-treated animals). Most significantly, when treated twice daily with oral ALS 1-0635, rats with surgically induced medial meniscus tear exhibited histologic evidence of chondroprotection and reduced cartilage degeneration, without observable musculoskeletal toxicity.

Conclusion

The compounds investigated in this study represent a novel class of MMP-13 inhibitors. They are mechanistically distinct from previously reported broad-spectrum MMP inhibitors and do not exhibit the problems previously associated with these inhibitors, including selectivity, poor pharmacokinetics, and MSS liability. MMP-13 inhibitors exert chondroprotective effects and can potentially modulate joint pain, and are, therefore, uniquely suited as potential disease-modifying osteoarthritis drugs.

Ancillary